Is Septerna Inc (SEPN) a Buy, Sell, or Hold?
NASDAQ : SEPN
Septerna Inc
$31.56 USD
-$2.51 (-7.37%)
- Volume
- 414.07K
- Average Volume
- 422.39K
- Market Capitalization
- $1.42B
- P/E Ratio
- -38.96
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $38.04
- Year Low
- $10.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.71
| Source | Headline |
|---|---|
|
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000. The transaction reduced direct Common Stock holdings by 93.7%, leaving 793 shares directly owned post-sale. fool.com - 2026-07-05 09:35:01 |
|
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares. fool.com - 2026-06-29 23:05:01 |
|
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago. The presentation will highlight the pharmacologic profile of SEP-479, a potent, sel. businesswire.com - 2026-06-08 08:00:00 |
|
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript seekingalpha.com - 2026-05-13 00:20:49 |
|
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.49 per share a year ago. zacks.com - 2026-05-11 18:25:23 |
|
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 globenewswire.com - 2026-05-11 16:01:00 |
|
Septerna to Present at Bank of America Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D. globenewswire.com - 2026-05-05 08:00:00 |
